Lakewood-Amedex Biotherapeutics Inc. (LABT) shareholders
Close on Nov 13, 2026Market cap $669.20KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HPW Investments Holding Ltd. | 3,435,501 | 24.04% | 13G (passive) | Apr 23, 2026 |
| WFI Equity, LLC | 1,259,684 | 8.80% | 13G (passive) | May 13, 2026 |
| Lindesfarne LLC | 203,360 | 9.88% | 13G (passive) | Apr 17, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LABT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Marex Group plc | 48,167 | 2.03% | $151.24K | New | 0.00% |
| Hrt Financial LP | 44,782 | 1.89% | $140.00K | New | 0.00% |
| UBS Group AG | 4,098 | 0.17% | $12.87K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 624 | 0.03% | $1.96K | New | 0.00% |
| Osaic Holdings, Inc. | 138 | 0.01% | $433 | New | 0.00% |
| Ronald Blue Trust, Inc. | 11 | 0.00% | $35 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 4.1% | 6 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kelvin Cooper | Chief Executive Officer, Director | 300,594 | 12.68% | May 1, 2026 |
| Thomas Balzer | Chief Medical Officer | 255,322 | 10.77% | May 1, 2026 |
| Peter Ceccacci | Chief Financial Officer | 468,148 | 19.76% | May 1, 2026 |
| Joseph Edward Tucker | Director | 0 | – | May 6, 2026 |
| Leonard James DeRoma | Director | 187,736 | 7.92% | May 1, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 7 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lakewood-Amedex Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 218,302 shares on Sep 29, 2026 over the last 90 days.
See a number that looks wrong?